12.07.2015 Views

continuada - ABENFO-Nacional

continuada - ABENFO-Nacional

continuada - ABENFO-Nacional

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Referências1. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitisB: a historical overview. Vaccine 2008;26(49):6266‐73.2. WHO. Immunization surveillance, assessment and monitoring. Geneva: World HealthOrganization; 2007.3. Brasil. Programa <strong>Nacional</strong> de Imunizações 30 anos. Projetos, Programas e Relatórios In,Ministério da Saúde, 2003.4. Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, et al. Longtermprotection of hepatitis B vaccine 18 years after vaccination. J Infect 2008;57(5):404‐9.5. Hu Y, Wu Q, Xu B, Zhou Z, Wang Z, Zhou YH. Influence of maternal Antibody againsthepatitis B surface antigen on active immune response to hepatitis B vaccine in infants.Vaccine 2008;26(48):6064‐67.6. Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY, et al. Humoral and cellularimmune responses to a hepatitis B vaccine booster 15‐18 years after neonatalimmunization. J Infect Dis 2008;197(10):1419‐26.7. Yang YJ, Liu CC, Chen TJ, Lee MF, Chen SH, Shih HH, et al. Role of hepatitis Bimmunoglobulin in infants born to hepatitis B e antigen‐negative carrier mothers inTaiwan. Pediatr Infect Dis J 2003;22(7):584‐8.8. Ioshimoto LM, Rissato ML, Bonilha VS, Miyaki C, Raw II, Granovski N. Safety andimmunogenicity of hepatitis B vaccine ButaNG in adults. Rev Inst Med Trop Sao Paulo1999;41(3):191‐3.9. Isolani AP, Sversuti CS, Sell AM, Moliterno RA. Protection against hepatitis B by theButang recombinant vaccine in newborn children in South Brazil. Mem Inst Oswaldo Cruz2006;101(5):551‐3.ISBN: 978-85-63901-04-0

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!